Sort   by:  
 Page size 
A375P melanoma cells were treated with 1uM of the MEK inhibitor PD184352 or 0.4uM of the V600EBRAF inhibitor PLX4720 for 2hr, 6hr and 24hrs. DMSO treatment for 2hr, 6hr and 24hrs serves as the negative control Triplicate experiments were performed for DMSO, PD184352 and PLX4720 treatment at 3 timepo...
ORGANISM(S): Homo sapiens 
Transcripts (mRNA) during amino acid limitation after MEK was inhibited were analyzed. HepG2 cells were pretreated with MEK inhibitor, PD98059 for 1 hour, then incubated in complete medium and a medium depleted for Histidine for 8 hours. For Inhibitor treated cells, PD98059 was included in the mediu...
ORGANISM(S): Homo sapiens 
Data from ProteomeXchange, PXD ID: PXD000528. Experiment: GM_NKI_NRAS_Phospho_Mix2, file: OR9_20130426_GM_NKI_NRAS_Phospho_Mix2_repl1_ReRunFr10.mzml. Published as part of Pigment Cell Melanoma Res. 2015 Feb 28 . From the Abstract: {{i}} No effective targeted therapy is currently available for NRAS ...
ORGANISM(S): Homo_sapiens_viruses, Human 
Neurofibromatosis Type 1 (NF1) patients develop benign neurofibromas and malignant peripheral nerve sheath tumors (MPNST). These incurable peripheral nerve tumors result from loss of NF1 tumor suppressor gene function, causing hyperactive Ras signaling. Activated Ras controls numerous downstream eff...
ORGANISM(S): Mus musculus 
Identification of MEK-ERK or p38MAPK dependent genes in human monocyte derived dendritic cells. Dendritic cells (DC) promote tolerance or immunity depending on their maturation state. Previous studies have revealed that DC maturation is enhanced or accelerated upon MEK-ERK signaling pathway inhibiti...
ORGANISM(S): Homo sapiens 
Cancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression ...
Anticancer drug development is an inefficient process, with potential therapeutics demonstrating a high attrition rate due to lack of efficacy in Phase II/III testing. In an effort to develop improved pre-clinical predictors of efficacy, we and others have turned to testing in genetically engineere...
ORGANISM(S): Mus musculus 
Since direct pharmacological inhibition of RAS has thus far been unsuccessful, we explored system biology approaches to identify synergistic drug combination(s) that can mimic direct RAS inhibition. Leveraging an inducible mouse model of NRAS-mutant melanoma, we compare pharmacological MEK inhibitio...
ORGANISM(S): Mus musculus 
We identified genome-wide binding patterns of CIC in several different cell types and find that CIC target genes are enriched for MAPK effector genes involved in cell cycle regulation and proliferation. CIC binding to its target genes is abolished by high MAPK activity, which leads to hyperacetylati...
ORGANISM(S): Homo sapiens 
Microarray expression analysis to identify global changes in transcription in response to RAF inhibition. Genes under RAF control were identified in a panel of BRAFV600E tumor cells, following the short-term inhibition of RAF using a pan-RAF kinase inhibitor, PLX4032 (Plexxikon). For comparison with...
ORGANISM(S): Homo sapiens 
Sort   by:  
 Page size